Daiichi Sankyo Bonds, 1.776% 24jun2019, JPY (FIGI BBG000042XK3, 00024568, JP347535B969)
Domestic bonds, Senior Unsecured
Domestic bonds, Senior Unsecured
Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market
Get accessBond parameters,
prospectuses
Analyze the data in the most efficient way
Current & historical quotes from 400+ stock exchanges & OTC market
Credit ratings, financial reports
Explore the most comprehensive database
1 000 000
bonds
80 234
stocks
167 970
ETF & Funds
70 000
indices
Track your portfolio in the most efficient way
full data on over 900 000 bonds, 80 000 stocks, 116 000 ETF & Funds; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & financial reports; user-friendly interface; available anywhere via Website, Excel Add-in and Mobile app.
Register|
Daiichi Sankyo Company, Limited (第一三共株式会社 Daiichi Sankyō Kabushiki-kaisha?) is a global pharmaceutical company and the second largest pharmaceutical company in Japan. It achieved JPY 1,148.2 billion in revenue in 2013. The company owns the American biotechnology ...
Daiichi Sankyo Company, Limited (第一三共株式会社 Daiichi Sankyō Kabushiki-kaisha?) is a global pharmaceutical company and the second largest pharmaceutical company in Japan. It achieved JPY 1,148.2 billion in revenue in 2013. The company owns the American biotechnology company Plexxikon, the German biotechnology company U3 Pharma and recently sold Ranbaxy Laboratories in India. Daiichi Sankyo Co., Ltd. is the producer of Benicar (Olmesartan), an angiotensin II receptor antagonist and top selling drug in the U.S. Global sales of Olmesartan in 2013 were 300.2 billion yen.
|
|
|
|
|
|
|
|
|
Explore the most comprehensive database
1 000 000
bonds
80 234
stocks
167 970
ETF & Funds
70 000
indices
Track your portfolio in the most efficient way
full data on over 900 000 bonds, 80 000 stocks, 116 000 ETF & Funds; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & financial reports; user-friendly interface; available anywhere via Website, Excel Add-in and Mobile app.
Register| 20/08/2025 | Upcoming Issue: Daiichi Sankyo 1Y |
| 20/08/2025 | Upcoming Issue: Daiichi Sankyo 7Y |
| 20/08/2025 | Upcoming Issue: Daiichi Sankyo 5Y |
| 20/08/2025 | Upcoming Issue: Daiichi Sankyo 3Y |
| 31/01/2025 | Daiichi Sankyo's Nine-Month Profit Jumps 28% |